Sage Group News

Opportunity for Leadership in Predictive Biomarker Diagnostics for Pre-Eclampsia

Metabolomic Diagnostics (“MetaDx”; is a Cork, Ireland-based predictive biomarker diagnostics company with novel intellectual property and a breakthrough approach to predicting pre-eclampsia in pregnant women. It also has a pipeline of additional metabolomic biomarker tests for additional health issues faced by pregnant women and their babies, including pre-term birth. Sage Group is representing MetaDx in a search for one or more commercial partners. Pre-eclampsia strikes ca. 5% of first time pregnancies, affecting 500,000 women and killing 75,000 babies each year. The PrePsia™ test has been developed by MetaDx in collaboration with Prof. Louise Kenny at Univer